My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
June 2015
TOP STORIES
Journal Club

In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine

    Click
    here for the previous edition of Journal Club. For a review of other recent research in the infectious diseases literature, see “In the Literature,” by Stanley Deresinski, MD, FIDSA, in each issue of Clinical Infectious Diseases.

    Treatment of Symptomatic Congenital CMV: Is Six Months Better Than Six Weeks?
    Reviewed by Terri Stillwell, MD

    Cytomegalovirus (CMV) is the most common cause of congenital viral infection. Many neonates with congenital CMV are asymptomatic, with only about 10 percent exhibiting symptoms at birth. However, despite being asymptomatic, some infected neonates can go on to develop hearing loss. Additionally, those that are symptomatic at birth can have progression of existing symptoms or development of additional complications later in life.

    Previous studies have found that, for symptomatic neonates with central nervous system (CNS) involvement treated within the first month of life, six weeks of antiviral therapy led to improved hearing and neurologic outcomes. A recent New England Journal of Medicine article goes a step further, evaluating the benefit of six months of treatment in comparison to six weeks of treatment.

    From June 2008 through May 2011, investigators randomized 96 infants with symptomatic congenital CMV infection to one of two arms: 47 received six weeks of valganciclovir plus four and a half months of placebo; 49 received six months of valganciclovir. The study’s primary endpoint evaluated change in “best-ear” hearing at six months. Secondary end points included change in hearing and neurologic outcomes at 12 and 24 months; medication side effects were also assessed.

    While the change in six-month best-ear hearing was the same for both treatment groups, significant differences were seen when assessing the secondary endpoints. When adjusting for baseline CNS involvement, total-ear hearing at 12 months was more likely maintained or improved in those treated with six months of valganciclovir. Also, with CNS-adjusted results, those treated with six months of valganciclovir had significantly higher scores on neurologic testing at 24 months. No significant medication side effects were seen between the two groups.

    This study suggests that six months of valganciclovir in symptomatic congenital CMV infection has a positive effect on long-term outcomes. Additional studies are needed to determine if comparable benefit can be achieved in asymptomatic infections.

    (Kimberlin et al. N Engl J Med. 2015;372:933-943.)

    A New Tenofovir Formulation: Fewer Renal and Bone Effects? 
    Reviewed by George R. Thompson III, MD

    Tenofovir disoproxil fumarate is included in four of the five regimens currently recommended for HIV-infected patients naïve to antiretroviral therapy. Although highly potent, safe, and widely used, tenofovir disoproxil fumarate causes nephrotoxicity (including proximal tubular injury) in a small but significant number of patients, and has also been linked to decreases in bone mineral density.

    Tenofovir disoproxil fumarate is metabolized to tenofovir and thereafter metabolized in cells to tenofovir-diphosphate (the active drug). High plasma levels of tenofovir have been associated with the toxicities mentioned above, and thus a novel tenofovir prodrug, tenofovir alafenamide, was developed. This formulation results in four times higher intracellular concentrations allowing for much lower doses to be administered, potentially reducing side-effects.

    In a recent article published online in The Lancet, researchers reported the results of two phase 3, double-blind comparative trials of tenofovir alafenamide versus tenofovir disoproxil fumarate (both coformulated with elvitegravir, cobicistat, and emtricitabine). The findings showed similar antiviral activity of both formulations with a significant reduced effect of tenofovir alafenamide compared to tenofovir disoproxil fumarate on patient glomerular filtration rate (p<0.0001), tubular proteinuria (p<0.0001), and bone mineral density (p<0.0001).


    The high rate of virologic success in these trials, with a concurrent reduction in both renal and bone effects observed in patients treated with tenofovir alafenamide, suggests this may become the preferred formulation.

    (Sax et al. Lancet. published online: April 15, 2015.)

    Back to Top

    For a review of other recent research in the infectious diseases literature, see “In the Literature,” by Stanley Deresinski, MD, FIDSA, in each issue of Clinical Infectious Diseases:

    June 15
    • Ebola in West Africa: Getting Ready for What Comes Next -- Measles and More
    • Optimal Treatment of Uncomplicated Malaria due to Chloroquine-Resistant Plasmodium falciparum in Returned Travelers
    • Case Vignette: Legionella Infection of an Infant Born in a Bath
    • Case Vignette: Toscana Encephalitis in a U.S. Traveler to Italy
    June 1
    • Staphylococcus aureus Bacteremia and Endovascular Device Infection
    • The “Fat City” Sewage Microbiome
    • Case Vignette: African Histoplasmosis in India
    • Case Vignette: Cerebral Chagas in a Transplant Recipient


    < Previous Article |

    Post a comment

    Your name:

    Your comment:


    PATIENT CARE AND SCIENCE
    FDA Cautions About Dose Confusion and Medication Errors for Antibacterial Drug Zerbaxa
    Foundation to Develop Database of C. difficile Providers
    CLINICAL PRACTICE MANAGEMENT
    So Long SGR! What’s Next, and How Will MACRA Affect You?
    CMS Proposes Changes to Meaningful Use Program; ONC Updates HIT Certification Criteria
    IDSA Offers Discussion Board, Other Resources on Contract Negotiations
    POLICY AND ADVOCACY
    IDSA Members Urge Increased NIH Funding on Capitol Hill
    Help HIVMA Advocate for HIV Funding and Syringe Exchange
    HOPE Act Springs Forward
    Weigh in on FDA Proposed Changes to Blood Donor Deferral Policy
    Societies Provide Comments to NIH on Improving Impact and Sustainability of Biomedical Research
    GLOBAL ID
    Science Speaks: Global HIV, TB and Ebola Research and Responses
    EDUCATION AND RESOURCES
    IDSA Foundation Joins the Combined Federal Campaign
    Courses in Antimicrobial Stewardship
    Updated Lyme Disease Case Study Course
    YOU AND YOUR COLLEAGUES
    Reminder: CID Editor-in-Chief Search is On!
    Members on the Move
    Member Report
    FROM THE PRESIDENT
    Concerned About Changes to the ABIM MOC Program? IDSA is Working for You
    TOP STORIES
    Big Advances in Antibiotic Stewardship and R&D Policies
    MERS: The Emergence Continues -- Learn the Latest at IDWeek
    Thank You From IDSA
    Journal Club
    IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
    To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
    If you are still having problems receiving our communications,
    see our white-listing page for more details.